NN9277 / Novo Nordisk - LARVOL DELTA

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity. (PubMed, Mol Metab) - "Although treatment with NN1177 was associated with dose-dependent and clinically relevant weight loss, the observed safety signals precluded further clinical development."

Journal • P1 data • Genetic Disorders • Inflammation • Obesity • CRP

Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. (PubMed, Expert Opin Emerg Drugs) - "There is a strong interest in developing obesity treatments based on glucagon-like peptide-1 (GLP-1) agonism, which have proved to limit morbidity and mortality in type 2 diabetes.Areas covered: This review provides an overview of current compounds containing GLP-1 receptor agonism in clinical development for obesity, with mono-activity at the GLP-1 receptor (PF-0688296, glutazumab, semaglutide) or engaging one or more other endogenous hormonal systems involved in energy balance and metabolism, including glucagon, oxyntomodulin, glucose-dependent inhibitory peptide and amylin (CT-868, CT-388, AMG 133, tirzepatide, NNC9204-1177, JNJ-54728518, SAR425899, pegapamodutide, MK8521, cotadutide, efinopegdutide, BI-456906, cagrilintide + semaglutide 2,4 mg, HM15211, NNC9204-1706).Expert opinion: Many novel compounds employing GLP-1 receptor agonism are in clinical development. Semaglutide is farthest in clinical development and will presumably become a benchmark for this class of..."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity (clinicaltrials.gov) - P1; N=99; Completed; Sponsor: Novo Nordisk A/S; N=72 ➔ 99

Clinical • Enrollment change

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People (clinicaltrials.gov) - P1; N=45; Completed; Sponsor: Novo Nordisk A/S; Active, not recruiting ➔ Completed

Clinical • Trial completion

Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity (clinicaltrials.gov) - P1; N=72; Completed; Sponsor: Novo Nordisk A/S; Active, not recruiting ➔ Completed

Clinical • Trial completion

Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity (clinicaltrials.gov) - P1; N=87; Active, not recruiting; Sponsor: Novo Nordisk A/S; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People (clinicaltrials.gov) - P1; N=45; Active, not recruiting; Sponsor: Novo Nordisk A/S; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People (clinicaltrials.gov) - P1; N=45; Recruiting; Sponsor: Novo Nordisk A/S; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People (clinicaltrials.gov) - P1; N=45; Not yet recruiting; Sponsor: Novo Nordisk A/S

Clinical • New P1 trial

Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity (clinicaltrials.gov) - P1; N=87; Recruiting; Sponsor: Novo Nordisk A/S; Completed ➔ Recruiting; Trial completion date: May 2019 ➔ Dec 2019; Trial primary completion date: May 2019 ➔ Dec 2019

Clinical • Enrollment open • Trial completion date • Trial primary completion date

Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity (clinicaltrials.gov) - P1; N=87; Completed; Sponsor: Novo Nordisk A/S; Active, not recruiting ➔ Completed

Clinical • Trial completion

Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity (clinicaltrials.gov) - P1; N=72; Active, not recruiting; Sponsor: Novo Nordisk A/S; Trial completion date: Dec 2018 ➔ May 2019; Recruiting ➔ Active, not recruiting; Trial primary completion date: Dec 2018 ➔ May 2019

Clinical • Enrollment closed • Trial completion date • Trial primary completion date